Aim and Objective: Actinomycetes produce structurally unique secondary metabolites with
pharmaceutically essential bioactivities. Salinispora, an obligate marine actinomycete, produces
structurally varied and unique secondary metabolites. There is plenty of scope for development of
drugs from the novel compounds isolated from Salinispora. Anticancer, antibacterial and anti-protozoa
activities have been shown for Salinosporamides A, B and C, the secondary metabolites identified from
Salinispora, which make them interesting subjects for further extended biological activity prediction.
Material and Methods: An in silico ligand based-pharmacophore approach was used for the prediction
of extended biological targets for salinosporamide A, B and C. Pharmacophore models of
salinosporamide A, B and C were generated individually and screened against known drug databases.
The drugs with best fitness score were shortlisted, and their respective targets pertaining to their
bioactivity were retrieved. The predicted biological drug targets were docked with salinosporamide A,
B and C for validation.
Results: The glucocorticoid receptor and methionine aminopeptidase 2 showed good docking score and
binding energy with salinosporamide A, B and C. Molecular dynamics studies of the protein-ligand
complexes showed stable interactions suggesting that the predicted new targets for salinosporamides
might be promising.
Conclusions: The glucocorticoid receptor and methionine aminopeptidase 2 could be possible new
drug targets of bioactivity of salinosporamides. These proteins could be the druggable targets for antiinflammatory
and anticancer activity of salinosporamides.